Circio selected for oral presentation at prestigious ASGCT annual meeting

Oslo, Norway, 18 March 2026 â€" Circio Holding ASA (OSE: CRNA), a biotechnology company developing novel circular RNA expression technology for gene and cell therapy, today announces that it has been selected for an oral presentation at the American Society of Gene and Cell Therapy annual meeting in Boston 11-15 May 2026.

The ASGCT annual meeting is the largest and most prestigious gene and cell therapy conference globally, and widely attended by pharmaceutical and biotech professionals, academics and life science media. Only a small number of submitted abstracts are accepted for oral presentation.

“ASGCT is the most important event of the year in our field, and we are very honored that the scientific committee has selected one of Circio´s gene therapy abstracts for an oral presentation,” said Dr. Thomas B Hansen, CTO of Circio. “This is an ideal opportunity to demonstrate to a broad industry audience how our circVec technology platform significantly enhances traditional gene and cell therapies. It is also an important arena to meet with both existing and prospective partners to support our R&D goals and create future business opportunities.”

Circio has submitted two abstracts for ASGCT 2026, of which one has been selected for oral presentation and one for poster presentation. Further information about the Circio presentations and the full abstract texts will be released on the general abstract publication date, 13 April 2026.

For further information, please contact:Erik Digman Wiklund, CEOPhone: +47 413 33 536Email: [email protected]

Neil Hunter â€" Hunter PRPhone: +44 782 125 5568Email: [email protected]

About CircioBuilding circular RNA expression systems for enhanced gene and cell therapies

Circio Holding ASA is a biotechnology company developing novel circular RNA expression technology for gene and cell therapy.

Circio has established a unique circular RNA (circRNA) vector expression technology for next generation RNA, DNA and viral therapeutics. The proprietary circVec platform is based on a modular genetic construct designed for efficient biogenesis of multifunctional circRNA inside target cells. The circVec platform has applications in multiple therapeutic settings, including genetic medicine, cell therapy and chronic disease. It has demonstrated 75-fold increased RNA half-life and up to 40-fold enhanced protein expression vs. conventional mRNA-based viral and non-viral vector systems, with the potential to become a new gold-standard gene expression technology. The circVec R&D activities are being conducted by the wholly owned subsidiary Circio AB in Stockholm, Sweden.